Global Alzheimer�s Disease Drugs Market and Pipeline Drugs Market Analysis to 2020

Global Alzheimer�s Disease Drugs Market And Pipeline Drugs Market Analysis To 2020

With the ageing population, the number of patients suffering from Alzheimers disease is predicted to grow during the forecast period. Alzheimer`s treatment is a high risk, high reward market. Drugs currently available in the market have reached maturity; patent of leading drugs have expired. The current unmet needs represent a huge opportunity for pharmaceutical companies.

Alzheimer`s disease is a devastating condition for those afflicted as well as their family members and caregivers; the situation is only getting worse as the population ages. With the ageing global population, the number of patients suffering from Alzheimers disease is predicted to grow during the forecasting period. Alzheimer`s treatment is a high risk, high reward market. Drugs currently available in the market have reached maturity; patent of leading drugs have expired. The current unmet needs represent a huge opportunity for pharmaceutical companies which are developing targeted novel therapies.

Global Alzheimers Disease Drugs Market and Pipeline Drugs Analysis: In 2014, the global market for Alzheimers disease drugs was dominated by Namenda and Exelon. Aricept and Memary stands at the third and fourth spot respectively in terms of Alzheimers disease drugs sales in 2014. Ebixa, Razadyne/Reminyl, Rivastach and Nootropil are the other popular drugs in the Alzheimers disease market. With the patent expiration of popular drugs the sales of the Alzheimers drugs has also declined. However, there are several pipeline drugs like Solanezumab, Gantenerumab, Crenezumab and Lu AE58054 among others which are likely to hit the market during the period 2017 - 2020.

Global Alzheimers Disease Country Wise Analysis: In the Alzheimers disease drugs market, the United States is the largest market. Japan is the second leading market for Alzheimers disease drugs market accounting for XXX% market share in 2014. China stands at the third spot in the global Alzheimers disease drugs market being followed by India with XXX% share in the same year. The EU5 countries together accounted for over XXX% share of the global Alzheimers disease drugs market in 2014.

iGATE RESEARCH report titled "Global Alzheimer`s Disease Drugs Market and Pipeline Drugs Market Analysis to 2020" is a 150 page report with 74 Figures and 10 Tables. This report analyses the Alzheimers Disease Drugs Market, Alzheimers Disease Pipeline Drugs Market and Clinical Trials Analysis, Alzheimers Disease - Country Wise Drugs Market, Country Wise Alzheimers Disease Prevalence, Major Deals in Alzheimers Disease Drugs Market Landscape, Funding in Alzheimers Disease Drugs Research, Driving Factors and Challenges for Alzheimers Disease Drugs Market.

The Alzheimers Disease Drugs Market has been analyzed from 7 View Points:

1. Alzheimers Disease - Drugs Sales and Forecast
2. Alzheimers Disease - Pipeline Drugs Sales Forecast
3. Alzheimers Disease Drugs - Country Wise Market and Forecast
4. Alzheimers Disease - Country Wise Prevalence and Forecast
5. Alzheimers Disease - Pipeline Drugs Clinical Trials Analysis
6. Alzheimers Disease - Major Deals in Alzheimes Drugs Market
7. Alzheimers Disease - Funding in Alzheimers Disease Research

The Top 9 Alzheimers Disease Drugs covered in the report are as follows:

1. Exelon
2. Razadyne/Reminyl
3. Memary
4. Ebixa
5. Aricept
6. Rivastach
7. Namenda
8. Nootropil
9. Namzaric

The 7 Pipeline Alzheimers Disease Drugs covered in the report are as follows:

1. Solanezumab
2. ABT-126
3. idalopirdine
4. Gantenerumab
5. Crenezumab
6. Lu AE58054
7. BIIB037

The 9 Countries Alzheimers Disease Drugs Market covered in the report are as follows:

1. United States
2. France
3. Germany
4. Italy
5. Spain
6. United Kingdom
7. Japan
8. China
9. India

The Alzheimers Disease Drugs Major Deals covered in the report are as follows:

1. Strategic Alliance
2. Licensing Agreement
3. Collaboration Deals
4. Mergers and Acquisitions

Data Sources

iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.

Research Methodologies

Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.

Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government And NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries And Local Councils and a large number of Paid Databases.

1. Executive Summary

2. Global Alzheimers Disease - Drugs Market and Prevalence Analysis

2.1 Global Alzheimers Disease - Drugs Market and Forecast (2010 - 2020)
2.2 Global Alzheimers Disease - Prevalence and Forecast (2010 - 2020)

3. Global Alzheimers Disease - Country Wise Market Share and Forecast (2013 - 2020)

4. Global Alzheimers Disease - Drugs Sales and Forecast To 2020

4.1 Exelon (Rivastigmine) Sales and Forecast
4.2 Razadyne/Reminyl Sales and Forecast
4.3 Memary (Memantine) Sales and Forecast
4.4 Ebixa (Memantine) Sales and Forecast
4.5 Aricept (Donepezil) Sales and Forecast
4.6 Rivastach Sales and Forecast
4.7 Namenda (Memantine) Sales and Forecast
4.8 Nootropil (Piracetam) Sales and Forecast
4.9 Namzaric (Memantine and Donepezil) Sales and Forecast

5. Global Alzheimers Disease - Pipeline Drugs Analysis and Sales Forecast

5.1 Solanezumab Drugs Analysis and Sales Forecast

5.1.1   About Solanezumab
5.1.2   Clinical Trials
5.1.3   Solanezumab Drugs Sales Forecast

5.2 ABT-126 Drugs Analysis and Sales Forecast

5.2.1   About ABT-126
5.2.2   Clinical Trials
5.2.3   ABT-126 Drugs Sales Forecast

5.3 Idalopirdine Drugs Analysis and Sales Forecast

5.3.1 About Idalopirdine
5.3.2 Clinical Trials
5.3.3 Idalopirdine Drugs Sales Forecast

5.4 Gantenerumab Drugs Analysis and Sales Forecast

5.4.1   About Gantenerumab
5.4.2   Clinical Trials
5.4.3   Gantenerumab Drugs Sales Forecast

5.5 Crenezumab Drugs Analysis and Sales Forecast

5.5.1   About Crenezumab
5.5.2   Clinical Trials
5.5.3   Crenezumab Drugs Sales Forecast

5.6 Lu AE58054 Drugs Analysis and Sales Forecast

5.6.1   About Lu AE58054
5.6.2   Clinical Trials
5.6.3   Lu AE58054 Drugs Sales Forecast

5.7 BIIB037 Drugs Analysis and Sales Forecast

5.7.1   About BIIB037
5.7.2   Clinical Trials
5.7.3   BIIB037 Drugs Sales Forecast

6. Alzheimers Disease Drugs Market and Prevalence - Country Wise Analysis

6.1 United States - Alzheimers Disease Drugs Market and Prevalence Analysis

6.1.1 United States - Alzheimers Disease Drugs Market and Forecast (2013 - 2020)
6.1.2 United States - Alzheimers Disease Prevalence and Forecast (2010 - 2020)

6.2 France - Alzheimers Disease Drugs Market and Prevalence Analysis

6.2.1 France - Alzheimers Disease Drugs Market and Forecast (2013 - 2020)
6.2.2 France - Alzheimers Disease Prevalence and Forecast (2012 - 2020)

6.3 Germany - Alzheimers Disease Drugs Market and Prevalence Analysis

6.3.1 Germany - Alzheimers Disease Drugs Market and Forecast (2013 - 2020)
6.3.2 Germany - Alzheimers Disease Prevalence and Forecast (2012 - 2020)

6.4 Italy - Alzheimers Disease Drugs Market and Prevalence Analysis

6.4.1 Italy - Alzheimers Disease Drugs Market and Forecast (2013 - 2020)
6.4.2 Italy - Alzheimers Disease Prevalence and Forecast (2012 - 2020)

6.5 Spain - Alzheimers Disease Drugs Market and Prevalence Analysis

6.5.1 Spain - Alzheimers Disease Drugs Market and Forecast (2013 - 2020)
6.5.2 Spain - Alzheimers Disease Prevalence and Forecast (2012 - 2020)

6.6 United Kingdom - Alzheimers Disease Drugs Market and Prevalence Analysis

6.6.1 United Kingdom - Alzheimers Disease Drugs Market and Forecast (2013 - 2020)
6.6.2 United Kingdom - Alzheimers Disease Prevalence and Forecast (2012 - 2020)

6.7 Japan - Alzheimers Disease Drugs Market and Prevalence Analysis

6.7.1 Japan - Alzheimers Disease Drugs Market and Forecast (2013 - 2020)
6.7.2 Japan - Alzheimers Disease Prevalence and Forecast (2012 - 2020)

6.8 China - Alzheimers Disease Drugs Market and Prevalence Analysis

6.8.1 China - Alzheimers Disease Drugs Market and Forecast (2013 - 2020)
6.8.2 China - Alzheimers Disease Prevalence and Forecast (2010 - 2020)

6.9 India - Alzheimers Disease Drugs Market and Prevalence Analysis

6.9.1 India - Alzheimers Disease Drugs Market and Forecast (2013 - 2020)
6.9.2 India - Alzheimers Disease Prevalence and Forecast (2010 - 2020)

7. Global Alzheimers Disease Drugs Market - Major Deals Analysis

7.1 Global Alzheimers Disease Drugs Market - Strategic Alliance
7.2 Global Alzheimers Disease Drugs Market - Licensing Agreement
7.3 Global Alzheimers Disease Drugs Market - Collaboration Deals
7.4 Global Alzheimers Disease Drugs Market - Mergers and Acquisitions

8. Global Alzheimers Disease Drugs Research - Funding Analysis

8.1 National Institute of Health (2011 - 2016)
8.2 Alzheimers Association (2011 - 2014)
8.3 Cure Alzheimers Fund (2008 - 2014)
8.4 Alzheimers Drug Discovery Foundation (2008 - 2013)
8.5 BrightFocus Foundation (2010 - 2014)

9. Global Alzheimers Disease Drug Market - Driving Factors

9.1 Growing Aging Population

9.1.1 Global Ageing Indicators
9.1.2 Population Aged 60 or Over: World and Development Regions, 1950 - 2050
9.1.3 Worldwide - Distribution of Population Aged 60 Years or Over By Broad Age Group, 1950 - 2050

9.2 Unmet Medical Needs
9.3 Strong Pipeline Candidate Expected to Drive Alzheimers Disease Drugs Market
9.4 Future Drugs for Disease Modification in Alzheimers Disease

10. Global Alzheimers Disease Drug Market - Challenges

10.1 Lack of Validated Targets & Lack of Animal Models
10.2 Barriers in the Design and Implementation of Clinical Trials
10.3 Barriers in Academia and Regulatory Issues
10.4 Alzheimers Drug Failure: Insinuation for Future Research and Development in Neuroscience
10.5 Costly Alzheimers Drug Development Dissuade Drug Companies
10.6 Research Setbacks and Stepping Stones

10.7 Country Wise Barriers to Growth for Alzheimers Disease Drugs Market

10.7.1 Unite States
10.7.2 France
10.7.3 Germany
10.7.4 United Kingdom
10.7.5 Japan
10.7.6 China
10.7.7 India

List of Figures:

Figure 2-1: Global - Alzheimers Disease Drugs Market (Million US$), 2010 - 2014
Figure 2-2: Global - Forecast for Alzheimers Disease Drugs Market (Million US$), 2015 - 2020
Figure 2-3: Global - Alzheimers Disease Prevalence (Million), 2010 - 2014
Figure 2-4: Global - Forecast for Alzheimers Disease Prevalence (Million), 2015 - 2020

Figure 4-1: Global - Exelon Drugs Sales (Million US$), 2003 - 2014
Figure 4-2: Global - Forecast for Exelon Drugs Sales (Million US$), 2015 - 2020
Figure 4-3: Global - Razadyne/Reminyl Drugs Sales (Million US$), 2010 - 2014
Figure 4-4: Global - Forecast for Razadyne/Reminyl Drugs Sales (Million US$), 2015 - 2020
Figure 4-5: Global - Memary Drugs Sales (Million US$), 2011 - 2014
Figure 4-6: Global - Forecast for Memary Drugs Sales (Million US$), 2015 - 2019
Figure 4-7: Global - Ebixa Drugs Sales (Million US$), 2003 - 2014
Figure 4-8: Global - Forecast for Ebixa Drugs Sales (Million US$), 2015 - 2020
Figure 4-9: Global - Aricept Drugs Sales (Million US$), 2009 - 2014
Figure 4-10: Global - Forecast for Aricept Drugs Sales (Million US$), 2015 - 2019
Figure 4-11: Global - Rivastach Drugs Sales (Million US$), 2011 - 2014
Figure 4-12: Global - Forecast for Rivastach Drugs Sales (Million US$), 2015 - 2020
Figure 4-13: Global - Namenda Drugs Sales (Million US$), 2003 - 2014
Figure 4-14: Global - Forecast for Namenda Drugs Sales (Million US$), 2015 - 2020
Figure 4-15: Global - Nootropil Drugs Sales (Million US$), 2004 - 2014
Figure 4-16: Global - Forecast for Nootropil Drugs Sales (Million US$), 2015 - 2020
Figure 4-17: Global - Forecast for Namzaric Drugs Sales (Million US$), 2015 - 2020

Figure 5-1: Global - Forecast for Solanezumab Drugs Sales (Million US$), 2017 - 2020
Figure 5-2: Global - Forecast for ABT-126 Drugs Sales (Million US$), 2017 - 2020
Figure 5-3: Global - Forecast for Idalopirdine Drugs Sales (Million US$), 2017 - 2020
Figure 5-4: Global - Forecast for Gantenerumab Drugs Sales (Million US$), 2017 - 2020
Figure 5-5: Global - Forecast for Crenezumab Drugs Sales (Million US$), 2018 - 2020
Figure 5-6: Global - Forecast for Lu AE58054 Drugs Sales (Million US$), 2017 - 2019
Figure 5-7: Global - Forecast for BIIB037 Drugs Sales (Million US$), 2019 - 2020

Figure 6-1: United States - Alzheimers Disease Drugs Market (Million US$), 2013 - 2014
Figure 6-2: United States - Forecast for Alzheimers Disease Drugs Market (Million US$), 2015 - 2020
Figure 6-3: United States - Alzheimers Disease Prevalence (Thousand), 2012 - 2014
Figure 6-4: United States - Forecast for Alzheimers Disease Prevalence (Thousand), 2015 - 2020
Figure 6-5: France - Alzheimers Disease Drugs Market (Million US$), 2013 - 2014
Figure 6-6: France - Forecast for Alzheimers Disease Drugs Market (Million US$), 2015 - 2020
Figure 6-7: France - Alzheimers Disease Prevalence (Thousand), 2012 - 2014
Figure 6-8: France - Forecast for Alzheimers Disease Prevalence (Thousand), 2015 - 2020
Figure 6-9: Germany - Alzheimers Disease Drugs Market (Million US$), 2013 - 2014
Figure 6-10: Germany - Forecast for Alzheimers Disease Drugs Market (Million US$), 2015 - 2020
Figure 6-11: Germany - Alzheimers Disease Prevalence (Thousand), 2012 - 2014
Figure 6-12: Germany - Forecast for Alzheimers Disease Prevalence (Thousand), 2015 - 2020
Figure 6-13: Italy - Alzheimers Disease Drugs Market (Million US$), 2013 - 2014
Figure 6-14: Italy - Forecast for Alzheimers Disease Drugs Market (Million US$), 2015 - 2020
Figure 6-15: Italy - Alzheimers Disease Prevalence (Thousand), 2012 - 2014
Figure 6-16: Italy - Forecast for Alzheimers Disease Prevalence (Thousand), 2015 - 2020
Figure 6-17: Spain - Alzheimers Disease Drugs Market (Million US$), 2013 - 2014
Figure 6-18: Spain - Forecast for Alzheimers Disease Drugs Market (Million US$), 2015 - 2020
Figure 6-19: Spain - Alzheimers Disease Prevalence (Thousand), 2012 - 2014
Figure 6-20: Spain - Forecast for Alzheimers Disease Prevalence (Thousand), 2015 - 2020
Figure 6-21: United Kingdom - Alzheimers Disease Drugs Market (Million US$), 2013 - 2014
Figure 6-22: United Kingdom - Forecast for Alzheimers Disease Drugs Market (Million US$), 2015 - 2020
Figure 6-23: United Kingdom - Alzheimers Disease Prevalence (Thousand), 2012 - 2014
Figure 6-24: United Kingdom - Forecast for Alzheimers Disease Prevalence (Thousand), 2015 - 2020
Figure 6-25: Japan - Alzheimers Disease Drugs Market (Million US$), 2013 - 2014
Figure 6-26: Japan - Forecast for Alzheimers Disease Drugs Market (Million US$), 2015 - 2020
Figure 6-27: Japan - Alzheimers Disease Prevalence (Thousand), 2010 - 2014
Figure 6-28: Japan - Forecast for Alzheimers Disease Prevalence (Thousand), 2015 - 2020
Figure 6-29: China - Alzheimers Disease Drugs Market (Million US$), 2013 - 2014
Figure 6-30: China - Forecast for Alzheimers Disease Drugs Market (Million US$), 2015 - 2020
Figure 6-31: China - Alzheimers Disease Prevalence (Thousand), 2010 - 2014
Figure 6-32: China - Forecast for Alzheimers Disease Prevalence (Thousand), 2015 - 2020
Figure 6-33: India - Alzheimers Disease Drugs Market (Million US$), 2013 - 2014
Figure 6-34: India - Forecast for Alzheimers Disease Drugs Market (Million US$), 2015 - 2020
Figure 6-35: India - Alzheimers Disease Prevalence (Thousand), 2010 - 2014
Figure 6-36: India - Forecast for Alzheimers Disease Prevalence (Thousand), 2015 - 2020

Figure 8-1: National Institute of Health - Alzheimers Disease Research Funding (Million US$), 2011 - 2014
Figure 8-2: National Institute of Health - Forecast for Alzheimers Disease Research Funding (Million US$), 2015 - 2016
Figure 8-3: Alzheimers Association - Alzheimers Disease Research Funding (Million US$), 2011 - 2014
Figure 8-4: Cure Alzheimers Fund - Alzheimers Disease Research Funding (Million US$), 2008 - 2014
Figure 8-5: Alzheimers Drug Discovery Foundation - Alzheimers Disease Research Funding (Million US$), 2008 - 2013

Figure 9-1: Worldwide - Population Aged 60 or Over: World and Development Regions, 1950, 1975, 2009, 2025 & 2050
Figure 9-2: Worldwide - Old-Age Dependency Ratio: Major Areas, 2009 & 2050
Figure 9-3: Worldwide - Distribution of population aged 60 years or over by broad age group, 1950 - 2050
Figure 9-4: Global - Forecast for Alzheimers Disease Pipeline Drugs Market (Million US$), 2017 - 2020

Figure 10-1: Unsuccessful Alzheimers Drug Development (Number), 1998 - 2011

List of Tables:

Table 3-1: Country Wise - Alzheimers Disease Drugs Market Share (Percent), 2013 - 2014
Table 3-2: Country Wise - Forecast for Alzheimers Disease Drugs Market Share (Percent), 2015 - 2020

Table 7-1: Global Alzheimers Disease Drugs Market - Strategic Alliance, 2003 - 2015
Table 7-2: Global Alzheimers Disease Drugs Market - Licensing Agreement, 2007 - 2015
Table 7-3: Global Alzheimers Disease Drugs Market - Collaboration Deals, 2005 - 2015
Table 7-4: Global Alzheimers Disease Drugs Market - Mergers and Acquisitions, 2008 - 2015

Table 8-1: BrightFocus Foundation - Alzheimers Disease Research Funding (Million US$), 2010 - 2014

Table 9-1: Global - Ageing Indicators (Percent), 2011/2012 - 2050
Table 9-2: Global - Population (Number), 2011/2012 - 2050
Table 9-3: Ten Countries or Areas with the Aging Populations 1950,1980,2013,2050 and 2100(Medium Variant)

Global Alzheimer�s Disease Drugs Market And Pipeline Drugs Market Analysis To 2020

PRICING

Categories